


ORPHAN DRUGS ARE LOSING THEIR SPARKLE

For more than a decade, orphan drugs' growth has outpaced non-orphans. Niche products' share of worldwide prescription drug sales by value has doubled over the last decade, from less than 10% in 2014 to almost a fifth today.

**BUT THE GROWTH GAP
IS NARROWING...**

IN THE PIPELINE...

TOP 3 ORPHAN R&D PRODUCTS BASED ON NPV



With over \$1.2 billion in forecast 2028 sales and an NPV just shy of \$6bn, the “vanza triple” now overshadows the four next-biggest pipeline orphans.

ORPHAN DRUGS WILL GENERATE

\$185BN IN 2024 &
\$270BN IN 2028

But while orphan drug sales growth averaged almost **11% annually** in the ten years to 2023 yet will **barely make double digits** for the rest of this decade.

Evaluate
a norstella company

THE TOP SELLERS

The ten most valuable orphan drugs will collectively generate over \$57 billion in 2028.

2028

TOP 3 ORPHAN DRUGS IN 2028



THE TOP COMPANIES

Big Pharma continue to dominate the rankings
Top 3 Companies by Orphan Drugs in 2028



For more about the impact of the IRA, reformation of the US Orphan Drug Act and the role payers,

CHECK OUT THE FULL REPORT [HERE](#)

Evaluate
a norstella company